Cardio- and renoprotective antidiabetic therapy

A method for treating a patient having a cardiovascular and/or renal microvascular disease, the method comprising administering linagliptin, or a pharmaceutically acceptable salt thereof, optionally in combination with one or more other active agents, to said patient, wherein said linagliptin is administered in an amount of 5 mg per day, and

• wherein the patient has:
• (i) albuminuria, wherein the urine albumin creatinine ratio (UACR) of said patient is ≥30 mg/g creatinine or ≥30 milligrams albumin per liter of urine or ≥30 micrograms albumin per minute or ≥30 milligrams albumin per 24 hours, and wherein the patient had a previous macrovascular disease selected from the group consisting of:
• a) previous myocardial infarction,
• b) advanced coronary artery disease,
• c) high-risk single-vessel coronary artery disease,
• d) previous ischemic or haemorrhagic stroke,
• e) presence of carotid artery disease, and
• f) presence of peripheral artery disease;
• and/or
• (ii) impaired renal function selected from the group consisting of:
• impaired renal function with an estimated Glomerular Filtration Rate (eGFR) 15-45 mL/min/1.73 m2 with any urine albumin creatinine ratio (UACR), and
• impaired renal function with an eGFR≥45-75 mL/min/1.73 m2 with an urine albumin creatinine ratio (UACR)>200 mg/g creatinine or >200 milligrams albumin per liter of urine or >200 micrograms albumin per minute or >200 milligrams albumin per 24 hours.